Best Diffuse Large B Cell Lymphoma Podcasts (2025)

1
Chronic Lymphocytic Leukemia — Proceedings from a Symposium Held in Partnership with the American Oncology Network 51:19

Play Pause

2h ago51:19

51:19

Dr Kerry A Rogers from The Ohio State University in Columbus summarizes the treatment landscape and reviews relevant clinical datasets for patients with chronic lymphocytic leukemia. CME information and select publications here.

1
CAR T-Cell Therapy for Non-Hodgkin Lymphoma | Cancer Q&A — Discussing Common Questions Posed by Patients 58:30

1h ago58:30

58:30

Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Loretta J Nastoupil from CommonSpirit Mercy Hospital in Durango, Colorado, discuss the clinical applications of chimeric antigen receptor T-cell therapy for patients with non-Hodgkin lymphoma. CME information and select publications here.…

1
Toxicities Associated with CAR T-Cell Therapy — An Interview with Dr Matthew Lunning 52:03

4d ago52:03

52:03

Dr Matthew Lunning from the Fred and Pamela Buffett Cancer Center in Omaha, Nebraska, discusses recent updates on the management of toxicities associated with CAR T-cell therapy. CME information and select publications here.

1
TROP2 and TIGIT Therapies for Advanced NSCLC: Where Are We Today? 20:37

26d ago20:37

20:37

In this episode, Benjamin Levy, MD, FASCO, and Alex Spira, MD, PhD, FASCO, discuss the latest developments in targeting TROP2 and TIGIT for the treatment of lung cancer, including: TROP2-targeting ADCs: datopotamab deruxtecan, sacituzumab govitecan, sacituzumab tirumotecan TROP2 ADCS for patients with EGFR-mutated NSCLC TIGIT-targeting agents: domv…

1
Patient Education Resource: Non-Hodgkin Lymphoma — Clinical Experts Address Common Questions Posed by Patients About CAR T-Cell Therapy 59:42

23d ago59:42

59:42

Dr Jeremy S Abramson from Massachusetts General Hospital in Boston and Dr Manali Kamdar from the University of Colorado Cancer Center in Aurora discuss patient questions and experiences with CAR T-cell therapy for non-Hodgkin lymphoma. Educational information and select publications here.

1
Diffuse Large B-Cell Lymphoma and Follicular Lymphoma — Proceedings from a Multitumor Symposium in Partnership with Florida Cancer Specialists & Research Institute 1:00:13

29d ago1:00:13

1:00:13

Dr Matthew Lunning and Dr Sonali M Smith share their perspectives on the evolving therapeutic landscape for patients with diffuse large B-cell lymphoma and follicular lymphoma. CME information and select publications here.

1
A Newly Approved Targeted Combination Therapy for KRAS-Mutant Low-Grade Serous Ovarian Cancer 22:14

1M ago22:14

22:14

In this episode, Dr Rachel Grisham and Dr Kathleen Moore discuss newly approved treatments for low-grade serous ovarian cancer (LGSOC) and how recent research has transformed the therapeutic landscape for these patients, including: Molecular distinctions between low-grade and high-grade serous ovarian cancer that can guide therapy selection The rec…

1
CDH6-Targeting Antibody–Drug Conjugates in Ovarian Cancer: A Promising Treatment Approach 26:01

1M ago26:01

26:01

In this episode, Kathleen N. Moore, MD, MS, FASCO, and Isabelle Ray-Coquard, MD, PhD, discuss the emerging role of CDH6-targeting antibody–drug conjugates (ADCs) for ovarian cancer, including: Results of the phase I trial of raludotatug deruxtecan (R-DXd) in ovarian cancer Results of the phase II REJOICE-Ovarian01 study in patients with platinum-re…

1
Transforming Care in Cutaneous Squamous Cell Carcinoma: Integrating Immunotherapy Into Patient Care 35:16

1M ago35:16

35:16

In this podcast, Dr David Miller, MD, PhD, FAAD and Dr Vishal Patel, MD discuss the evolving treatment landscape and immunotherapeutic strategies for cutaneous squamous cell carcinoma (cSCC) based on key data from pivotal studies that are reshaping standards of care, including: Trials of neoadjuvant immunotherapies demonstrating remarkable response…

1
Paroxysmal Nocturnal Hemoglobinuria: Translating Pathobiology Into Modern Clinical Management 27:48

2M ago27:48

27:48

In this educational podcast discussion, Carlos M. De Castro, MD, and David Dingli, MD, PhD, FRCP, FRCPEd, FACP, FRCPath, explore paroxysmal nocturnal hemoglobinuria (PNH). They trace the evolution of treatment from early complement inhibitors to today’s expanding therapeutic options, emphasizing how these advances have transformed patient outcomes …

1
Acute Myeloid Leukemia — An Interview with Dr Eunice S Wang to Review Key Presentations from ASCO and EHA 54:59

1M ago54:59

54:59

Dr Eunice S Wang from Roswell Park Comprehensive Cancer Center in Buffalo, New York, discusses recent datasets and their implications for the current and future management of acute myeloid leukemia. CME information and select publications here.

1
Non-Hodgkin Lymphoma — The Implications of Recent Datasets for Current and Future Disease Management 57:59

2M ago57:59

57:59

Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, review recent datasets and their significance for the management of various forms of non-Hodgkin lymphoma. CME information and select publications here.

1
Advancing the Care of Patients With High-Risk HR-Positive/HER2-Negative Early Breast Cancer 26:10

2M ago26:10

26:10

In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative early breast cancer including insights on identifying high-risk disease considering clinical/pathological factors and gene expression assays and answering healthcare professional questions on h…

1
Advancing the Care of Patients With HR-Positive/HER2-Negative Metastatic Breast Cancer 23:57

2M ago23:57

23:57

In this podcast episode, breast cancer experts Manali Bhave, MD, and Erin F. Cobain, MD, discuss their management of patients with HR-positive/HER2-negative metastatic breast cancer including the current treatment algorithm, implementing genomic testing for assessing molecular resistance and guiding treatment decisions, and answering healthcare pro…

1
HER2-Positive Gastroesophageal Adenocarcinoma and Biliary Tract Cancers: Testing Recommendations and New Treatment Options 37:10

2M ago37:10

37:10

In this podcast episode, Amit Mahipal, MD, MPH, and Shubham Pant, MD, discuss new and emerging therapies for the personalized care of patients with HER2-positive gastroesophageal adenocarcinoma (GEA) and biliary tract cancer (BTC), including: Brief overview of BTC and GEA Approved HER2-directed therapies for BTC and GEA and their mechanisms of acti…

1
Follicular Lymphoma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual Meeting 59:34

2M ago59:34

59:34

Dr Jeremy S Abramson from Massachusetts General Hospital in Boston, Dr Jennifer Crombie from Dana-Farber Cancer Institute also in Boston and Dr Laurie H Sehn from the BC Cancer Centre for Lymphoid Cancer in Vancouver, British Columbia, Canada, discuss recent updates on available and novel treatment strategies for follicular lymphoma.  CE informatio…

1
Acute Myeloid Leukemia — An Interview with Dr Ghayas Issa on the Role of Menin Inhibitors 58:47

2M ago58:47

58:47

Dr Ghayas Issa from The University of Texas MD Anderson Cancer Center in Houston discusses data guiding the use of menin inhibitors for patients with acute myeloid leukemia and select alterations. CME information and select publications here.

1
Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual Meeting 58:29

2M ago58:29

58:29

Prof Meletios-Athanasios (Thanos) C Dimopoulos from Alexandra Hospital in Athens, Greece, Dr Hans Lee from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Joseph Mikhael from City of Hope Cancer Center in Phoenix, Arizona, and Dr Noopur Raje from Massachusetts General Hospital in Boston discuss recent updates on available and novel trea…

1
Oncology Nursing Update: Multiple Myeloma — An Interview with Dr Beth Faiman on CAR T-Cell Therapy 53:08

3M ago53:08

53:08

Dr Beth Faiman from Case Comprehensive Cancer Center in Cleveland, Ohio, discusses nursing considerations with CAR T-cell therapy for patients with multiple myeloma. NCPD information and select publications here.

1
Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 2 — An Interview with Dr Neel Pasricha on Adverse Event Management 54:23

3M ago54:23

54:23

Dr Neel Pasricha from the University of California, San Franciso, reviews corneal and other ophthalmic toxicities associated with antibody-drug conjugates and other cancer therapies and strategies for their prevention and management. CME information and select publications here.

1
Ocular Toxicities Associated with Antibody-Drug Conjugates and Other Cancer Therapies: Part 1 — Inside the Issue of Adverse Event Management 57:47

3M ago57:47

57:47

Prof Rebecca A Dent from National Cancer Centre Singapore, Dr Hans Lee from Sara Cannon Research Institute in Nashville, Tennessee, Dr Neel Pasricha from the University of California, San Francisco, and Dr Tiffany A Richards from The University of Texas MD Anderson Cancer Center in Houston, discuss strategies to manage ocular toxicities associated …

1
Key Decisions for Selecting Bispecific Antibodies in Follicular Lymphoma 22:53

3M ago22:53

22:53

In this episode, Dr Christopher Flowers and Dr John Allan discuss their experience with the use of CD20xCD3 bispecific antibodies in the treatment of patients with relapsed/refractory follicular lymphoma. They also their thoughts on key ongoing clinical trials with bispecific antibodies that they are excited about for their potential to change the …

1
Oncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Ms Charise Gleason 54:17

3M ago54:17

54:17

Ms Charise Gleason from Emory Healthcare in Atlanta, Georgia, discusses the evolution of first-line therapy for patients with multiple myeloma. NCPD information and select publications here.

1
Oncology Nursing Update: Newly Diagnosed Multiple Myeloma — An Interview with Prof Xavier Leleu 53:08

3M ago53:08

53:08

Prof Xavier Leleu from Poitiers University Hospital in Poitiers, France, discusses nursing considerations in the treatment of newly diagnosed multiple myeloma. NCPD information and select publications here.

1
Pancreatic Cancer Progress: Expert Insights on Treatment Choices and Collaborating with Patients 13:57

3M ago13:57

13:57

Listen in as Zev A. Wainberg, MD; Paul E. Oberstein, MD; and Mark O’Hara, MD, discuss the evolving treatment landscape for metastatic pancreatic cancer, including: How patients often present with disease-related symptoms Treatment selection considerations for the first-line and second-line setting How to approach palliative care discussions with pa…

1
Latest Advances in CAR T-Cell Therapy for Lymphomas and Multiple Myeloma 16:48

3M ago16:48

16:48

In this episode, Dr Brad Kahl and Dr Noopur Raje discuss the recent advances and emerging data for CAR T-cell therapy in lymphomas and multiple myeloma including the latest evidence from long-term clinical trial follow-up and real-world data, plus new data with CAR T-cell therapies in new lymphoma settings and novel CAR T-cell therapies currently u…

1
Relapsed/Refractory Multiple Myeloma — Oncology Q&A: Discussing Common Questions Posed by Patients 59:21

4M ago59:21

59:21

Dr Natalie S Callander and Dr Sagar Lonial provide clinical perspectives on the treatment and disease-management course for patients with relapsed/refractory multiple myeloma. CME information and select publications here.

1
CDK4/6 Inhibitors in HR-Positive/HER2-Negative Breast Cancer: Experts Answer Your Questions 20:20

4M ago20:20

20:20

In this episode, Drs William J. Gradishar, Heather McArthur, and Joanne Mortimer address audience questions from a recent live event on the use of CDK4/6 inhibitors in patients with early and metastatic breast cancer, including: Genomic testing options for assessing risk of recurrence Adjuvant treatment duration and holidays with CDK4/6 inhibitors …

1
Emerging DLL3-Targeted Therapies for Extrapulmonary Neuroendocrine Carcinomas 29:59

4M ago29:59

29:59

In this episode, Dr. Daniel Morgensztern and Dr. Jonathan Strosberg discuss the emerging role of DLL3-targeted agents in the management of extrapulmonary neuroendocrine carcinomas, including: The clinical implications of using DLL3 as a therapeutic target The impact of emerging DLL3-targeted therapies on evolving treatment paradigms How to incorpor…

1
Multiple Myeloma | Oncology Q&A — Patient Education Resource: Clinical Experts Address Common Questions Posed by Patients with Relapsed/Refractory Multiple Myeloma 1:02:11

4M ago1:02:11

1:02:11

For this patient-focused webinar, medical oncologist Dr Neil Love is joined by Dr Natalie S Callander from the University of Wisconsin Carbone Cancer Center in Madison and Dr Sagar Lonial from the Winship Cancer Institute of Emory University in Atlanta, Georgia, to discuss the patient experience associated with the diagnosis and treatment of relaps…

1
Highlights from the American Society of Clinical Oncology (ASCO) Annual Meeting — Driving Knowledge to Action: Building a Better Future 1:30:31

4M ago1:30:31

1:30:31

- Treatment Updates from ASCO 2025 on Lung Cancer- Supportive Care Issues- Treatment Updates from ASCO 2025 on Colorectal Cancer- Quality-of-Life Concerns- Update on Pancreas Cancer- Supportive Care Concerns- Update on Lymphoma- Communicating with Your Health Care Team- Updates on Leukemia from ASCO- Managing Treatment Side Effects- Updates on Mela…

1
Acute Myeloid Leukemia — An Interview with Dr Jorge Cortes on Optimal Management of FLT3 and IDH1/2 Mutations 43:01

4M ago43:01

43:01

Dr Jorge Cortes from Georgia Cancer Center at Augusta University discusses patient cases and summarizes current treatment approaches for FLT3- and IDH1/2-mutant acute myeloid leukemia. CME information and select publications here.By Dr. Neil Love

1
Available and Emerging Subcutaneous Immunotherapy Treatment Options for Patients With Cancer: A Pharmacy Perspective 24:49

4M ago24:49

24:49

In this episode, listen to Kelly Romo, PharmD, BCOP; and Shauna Kraft, PharmD, BCOP, share their takeaways from a live webinar on available emerging subcutaneous immunotherapy options for patients with cancer including: Basic mechanism of action and role of hyaluronidase in subcutaneous immunotherapy formulation and available dosing/schedules Avail…

1
Multiple Myeloma — Optimizing the Selection of First-Line Therapy 57:11

4M ago57:11

57:11

Prof Xavier Leleu and Dr Peter Voorhees review relevant clinical data regarding first-line treatment decisions for patients with multiple myeloma. CME information and select publications here.By Dr. Neil Love

1
Key Advances in Lymphomas and Acute Lymphocytic Leukemia From EHA and ICML 2025 39:12

5M ago39:12

39:12

In this podcast, Max S. Topp, MD, and Pier Luigi Zinzani, MD, PhD, explore the current and future implications of some of their top choices of studies in lymphomas and ALL presented at the EHA and ICML 2025 meetings. Program Abstracts: POLARGO: Rituximab, Gemcitabine and Oxaliplatin ± Polatuzumab Vedotin for R/R DLBCL ECHO: Rituximab-Bendamustine ±…

1
Experts Discuss Key Studies in Breast Cancer: Independent Conference Coverage of the 2025 ASCO Annual Meeting 35:02

5M ago35:02

35:02

In this episode, Kevin Kalinsky, MD, MS, FASCO, and Sara M. Tolaney, MD, MPH, discuss the most clinically relevant data in breast cancer presented at the 2025 ASCO Annual Meeting, including: DESTINY-Breast09: phase III trial of trastuzumab deruxtecan with or without pertuzumab vs THP as first-line treatment of HER2-positive advanced/metastatic brea…

1
Takeaways From a Large Educational Program on Available and Emerging Treatment Options for HER2-Positive mBC 18:04

5M ago18:04

18:04

In this episode, listen to Laura M. Spring, MD; and Shipra Gandhi, MD, MS, share their takeaways from a large educational program on available and emerging first-line treatment options for patients with HER2-positive mBC: Emerging new data from the phase IIII DESTINY-Breast09 trial of first-line treatment with trastuzumab deruxtecan ± pertuzumab vs…

1
A New Revolution in AML Treatment: Can Menin Inhibitors Follow the Path of FLT3 and IDH Inhibitors? 22:23

5M ago22:23

22:23

In this episode, Eunice Wang, MD and Eytan Stein, MD explore the latest key clinical updates on menin inhibitors in AML. This episode unpacks evolving treatment strategies and what these developments mean for patient care. Presenters: Eytan M. Stein, MD Chief, Leukemia Service Director, Program for Drug Development in Leukemia Associate Attending P…

1
BTK Inhibitors in CLL: Key Clinical Updates From ASCO & EHA 2025 21:24

5M ago21:24

21:24

In this episode, James Davis, PharmD, BCOP and Victoria Nachar, PharmD, BCOP summarize the latest key clinical updates on BTK inhibitors in CLL based on data recently presented at the annual ASCO and EHA meetings, including: The randomized phase III FLAIR trial The randomized phase III SEQUOIA trial The randomized phase III BRUIN CLL-321 trial Pres…

1
Chronic Lymphocytic Leukemia — Proceedings from a Session Held During the 2025 ASCO Annual Meeting 1:00:43

5M ago1:00:43

1:00:43

Dr Catherine Coombs and Dr William Wierda summarize major treatment advances in chronic lymphocytic leukemia presented at the 2025 American Society of Clinical Oncology Annual Meeting and review ongoing clinical trials. CME information and select publications here.By Dr. Neil Love

1
Incorporating Immune Checkpoint Inhibitors Across the Disease Spectrum of Hepatocellular Carcinoma 31:19

5M ago31:19

31:19

In this episode, Joseph W. Franses, MD, PhD; Neehar Parikh, MD, MS; and Mark Yarchoan, MD, share their thoughts on incorporating immune checkpoint inhibitors into the care of patients with HCC including: Clinical Considerations for Selecting First-line Immunotherapy Combinations for Metastatic HCC Overview of the Latest Data for the Combination of …

1
Personalized Pathways: Redefining Frontline Hodgkin Lymphoma Treatment Strategies 35:36

5M ago35:36

35:36

In this episode, Jonathan W. Friedberg, MD; Alex F. Herrera, MD; and Kara Kelly, MD, discuss the latest frontline treatment options for advanced Hodgkin lymphoma (HL) and approaches to personalizing treatment for the general patient population, older patients, and pediatric patients. This podcast was adapted from a live presentation held in May 202…

1
Multiple Myeloma — Proceedings from a Webinar Held in Conjunction with the 2025 ASCO Annual Meeting 58:41

5M ago58:41

58:41

Dr Ajay K Nooka from Winship Cancer Institute of Emory University in Atlanta, Georgia, and Dr Paul G Richardson from Dana-Farber Cancer Institute in Boston, Massachusetts, discuss recent updates on available and novel treatment strategies for multiple myeloma. CME information and select publications here.…

1
Experts Discuss CELMoDs in Myeloma 35:51

5M ago35:51

35:51

In this episode, Jesus Berdeja, MD; Amrita Krishnan, MD, FACP; and Sagar Lonial, MD, FACP, discuss key topics with CELMoD therapy for multiple myeloma, including: Mechanistic differences between CELMoDs and IMiDs Emerging data with CELMoDs and their potential therapeutic roles across the disease continuum of multiple myeloma The clinical implicatio…

1
For Oncology Nurses: Chronic Lymphocytic Leukemia — Proceedings from the 2025 Annual ONS Congress 1:30:22

5M ago1:30:22

1:30:22

Dr Bita Fakhri, Dr Jeff Sharman, and nurse practitioners Dr Jacqueline Broadway-Duren and Ms Corinne Hoffman discuss the current treatment landscape for chronic lymphocytic leukemia and strategies to mitigate and manage treatment-emergent adverse events. NCPD information and select publications here.…

1
Non-Hodgkin Lymphoma — Proceedings from a Session Held During the 2025 ASCO Annual Meeting 1:59:42

5M ago1:59:42

1:59:42

Dr Jeremy Abramson from Massachusetts General Hospital in Boston, Dr Joshua Brody from the Tisch Cancer Institute in New York, New York, Dr Christopher Flowers from The University of Texas MD Anderson Cancer Center in Houston, Dr Ann LaCasce from Dana-Farber Cancer Institute in Boston, Massachusetts, and Dr Tycel Phillips from City of Hope Comprehe…

1
For Oncology Nurses: Non-Hodgkin Lymphoma — Proceedings from the 2025 Annual ONS Congress 1:26:53

5M ago1:26:53

1:26:53

Dr Christopher Flowers and Dr Manali Kamdar summarize the clinical treatment landscape for patients with non-Hodgkin lymphoma, supported by clinical perspectives and management strategies from nurse practitioners Ms Robin Klebig and Ms Caitlin Murphy. NCPD information and select publications here.By Dr. Neil Love

1
For Oncology Nurses: Chronic Myeloid Leukemia — Proceedings from the 2025 Annual ONS Congress 1:26:22

6M ago1:26:22

1:26:22

Dr Michael Mauro, Dr Neil Shah, and nurse practitioners Ms Ilene Galinsky and Dr Sara Tinsley-Vance discuss important nursing considerations in the modern treatment of chronic myeloid leukemia. NCPD information and select publications here.By Dr. Neil Love

1
Addressing the LGBTQI+ Health Disparities Gap 56:55

5M ago56:55

56:55

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV- The LGBTQI+ Community’s Disproportionate Cancer Burden- Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers- Barriers to Health Care Access, Including Discrimination- Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housi…

1
Addressing the LGBTQI+ Health Disparities Gap 56:55

6M ago56:55

56:55

- Overview of Cancer & the LGBTQI+ Community, Including HIV & HPV- The LGBTQI+ Community’s Disproportionate Cancer Burden- Addressing the LGBTQI+ Health Disparities Gap, Including Mistrust of Health Care Providers- Barriers to Health Care Access, Including Discrimination- Health Care, Cancer Screening, Palliative & Supportive Care, Affordable Housi…